Push back early. Extend life.1,2

ERLEADA® is indicated in adult men for the treatment of metastatic
hormone-sensitive prostate cancer (mHSPC), in combination with ADT.*

IT'S HERE: The TITAN final analysis confirms the power of ERLEADA® + ADT to push back on progression.3
After 44 months of median follow-up, the analysis confirms a range of benefits for a broad population of patients with mHSPC.3


48% Reduction in Risk of Death After Adjusting for ~ 40% Crossover


~40% of PBO-treated patients crossed over to receive open- label APA at unblinding.

IPCW sensitivity analysis for crossover effect was prespecified in the statistical analysis plan.

IPCW, Inverse probability censoring weighted (sensitivity analysis); ITT, intent to treat.
IPCW method, Cale SR et aI., compute methods programs blomed. 2004; 75:45-49.


ADT, androgen deprivation therapy; HRQoL, health-related quality of life; mHSPC, metastatic hormone-sensitive prostate cancer; OS, overall survival; PSA, prostate-specific antigen.
*ERLEADA® is also indicated in adult men for the treatment of nori-metastatic castration-resistant prostate cancer (CRPC) who are at high risk of developing metastatic disease (PSA doubling time of 10 months, despite ADT).1
1Median OS was not reached in the ERLEADA® arm (HR: 0.65;95% CI:0.53-0.79; p<0.0001).3

1. ERLEADA® . Summary of Product Characteristics. Janssen-Cilag. Available at Accessed: February 2021.
2. Chi KN, et al. N Engl J Med. 2019;81(1):13–24.
3. Chi KN, et al. Final analysis results from TITAN: a phase 3 study of apalutamide (APA) vs placebo(PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receivingandrogen deprivation therapy (AOT). Available at: Accessed: February 2021.